Case study: High-throughput expression of SARS-CoV-2 viral antigens

Customer problem

  • Replacement for costly and inefficient mammalian (CHO, HEK) cell production of SARS-CoV-2 “Spike” receptor binding domain (RBD) variants required for protein subunit vaccine

Ingenza solution

  • Proprietary P. pastoris strains secreting RBD (COVID-19) vaccine components
  • Viable upstream/downstream manufacture and conjugation to subunit vaccine carrier
  • Highly cost-competitive with CHO, HEK manufacture and identical immunogenic performance
  • P. pastoris secreting SARS-CoV-2 RBD variants of concern
Build & Screen
  • Design and integration of genetic constructs
  • FACS supported visABLE® screening for jackpot clones with optimal productivity/stability
Pre-clinical performance
  • Highly immunogenic performance confirmed
  • Progressed to pre-clinical animal testing

Want to Know More?

We’d love to hear from you.